You are here: Industry Insights > INVOKANA

News List

Janssen’s Invokana secures FDA priority review status pharmaceutical-technology
May 24, 2019
Janssen Pharmaceutical has received priority review from the US Food and Drug Administration (FDA) for its Invokana (canagliflozin) medicine in type 2 diabetes (T2D) patients with chronic kidney disease (CKD).
FDA OKs J&J's Invokana for heart conditions biospectrumasia
November 26, 2018
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved INVOKANA (canagliflozin) to reduce the risk
Janssen Receives FDA Approval for INVOKANA contractpharma
November 01, 2018
To reduce risk of major adverse cardiovascular events, in adults with type 2 diabetes (T2D) who have established CV disease
Janssen gets FDA approval for Invokana to reduce risk of CV events pharmaceutical-technology
November 01, 2018
Janssen Pharmaceutical has received approval from the US Food and Drug Administration (FDA) for the use of Invokana (canagliflozin) to minimise the risk of major adverse cardiovascular (CV) events in adults.
EMA issues positive opinion to Janssen’s INVOKANA and VOKANAMET biospectrumasia
August 07, 2018
The positive opinion will now be reviewed by the European Commission, which has the authority to grant approval of the updated label.
INVOKANA® (canagliflozin) Demonstrated Significant Renal Protective Benefits in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease biospace
April 13, 2018
Johnson & Johnson Janssen Pharmaceuticals today announced an additional analysis of the landmark CANVAS project
INVOKANA reduces the risk of CV, MI and stroke pharmaaisa
July 06, 2017
Study results published in the New England Journal of Medicine and featured in a special symposium at the American Diabetes Association 77th Scientific Sessions.
INVOKANA reduces the risk of CV, MI and stroke pharmaasia
July 06, 2017
Study results published in the New England Journal of Medicine and featured in a special symposium at the American Diabetes Association 77th Scientific Sessions.